Zai Lab (ZLAB) Expected to Announce Quarterly Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Zai Lab to post earnings of ($0.38) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Zai Lab Stock Performance

ZLAB opened at $20.18 on Thursday. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -10.35 and a beta of 0.88. Zai Lab has a one year low of $15.96 and a one year high of $44.34. The business’s fifty day moving average is $18.14 and its two-hundred day moving average is $25.06.

Insider Buying and Selling at Zai Lab

In related news, insider Rafael Amado sold 10,787 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total value of $188,017.41. Following the completion of the sale, the insider directly owned 52,391 shares in the company, valued at approximately $913,175.13. The trade was a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.96% of the stock is currently owned by insiders.

Institutional Trading of Zai Lab

A hedge fund recently raised its stake in Zai Lab stock. Royal Bank of Canada lifted its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,771 shares of the company’s stock after buying an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. Institutional investors own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ZLAB. Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a research note on Wednesday, January 21st. JPMorgan Chase & Co. reduced their target price on Zai Lab from $46.00 to $39.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. UBS Group assumed coverage on Zai Lab in a research report on Wednesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Jefferies Financial Group raised Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. Finally, Zacks Research lowered Zai Lab from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.59.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.